New advances in medication for muscle disease in children

(University of Gothenburg) Spinraza, the gene therapy medication, also provides significant improvements in cases with the next most severe form of neuromuscular disease, spinal muscular atrophy (SMA), which afflicts children from 6 to 18 months of age. That is shown by a study published in the New England Journal of Medicine (NEJM).
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news